Olema Oncology
Olema Oncology (NASDAQ: OLMA) is a clinical-stage biopharmaceutical company developing targeted small-molecule therapies for ER+/HER2- metastatic breast cancer, with lead asset palazestrant (OP-1250) in two pivotal Phase 3 trials and OP-3136 (KAT6 inhibitor) in Phase 1.
- Company typePublic
- Founded2006
- HeadquartersSan Francisco, United States
- Headcount101–250
- GTM typeB2B
- OfferingHardware or Manufacturing
What Olema Oncology does
Olema Oncology (Olema Pharmaceuticals, Inc., NASDAQ: OLMA) is a clinical-stage biopharmaceutical company founded in 2006 and headquartered in San Francisco, California, with additional operations in Cambridge, Massachusetts. The company develops targeted small-molecule therapeutics for estrogen receptor-positive (ER+) breast cancer and other solid tumors, with its lead asset palazestrant (OP-1250) currently in two pivotal Phase 3 trials (OPERA-01 as monotherapy and OPERA-02 in combination with ribociclib) for ER+/HER2- metastatic breast cancer, and a second asset, OP-3136, a KAT6 inhibitor in Phase 1 development for breast, prostate, and lung cancers.
Palazestrant is a first-in-class complete estrogen receptor antagonist (CERAN) and selective estrogen receptor degrader (SERD) that fully blocks both AF1 and AF2 transcriptional activation domains through complete recruitment of the NCoR1 corepressor protein, yielding durable inhibition of ER-driven transcription regardless of ESR1 mutation status. OP-3136 is an orally available small molecule that selectively inhibits lysine acetyltransferase 6 (KAT6), an epigenetic target dysregulated in multiple tumor types, and has shown synergistic anti-tumor activity when combined with palazestrant. The company has secured clinical collaborations with Novartis (ribociclib supply for OPERA-02), Pfizer (palbociclib combination studies), and Bayer (darolutamide combination for OP-3136).
Olema is pre-revenue and pre-commercial, generating no product revenue today and reporting a net loss of $162.5 million in 2025 against a cash position of $505.4 million (runway into mid-2028). The revenue model anticipates US product sales upon a planned 2027 commercial launch of palazestrant, with a global commercial partner to be sought for ex-US markets. Approximately 91.78% institutional ownership reflects a public-equity-financed capital structure, with cumulative capital raises of roughly $648.5 million between September 2023 and November 2025, including a $218.5 million public offering in November 2025. The company employs 101-250 staff, with a recently expanded commercial strategy function preparing for launch.
Olema Oncology firmographics
Firmographics- Name
- Olema Oncology
- Legal name
- Olema Pharmaceuticals, Inc.
- Website
- https://olema.com
- Company type
- Public
- Founded year
- 2006
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Short description
- Olema Oncology (NASDAQ: OLMA) is a clinical-stage biopharmaceutical company developing targeted small-molecule therapies for ER+/HER2- metastatic breast cancer, with lead asset palazestrant (OP-1250) in two pivotal Phase 3 trials and OP-3136 (KAT6 inhibitor) in Phase 1.
- Ownership category
- akta.pro rank
Olema Oncology industry classification
Industry- Product category
- Oncology Drug Development
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Breast Oncology (HLAKAFAJ)
- akta.pro secondary industries
- Medical Oncology (HLAKAFAB), Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health) (HLAIAAAJ)
Keywords
Where Olema Oncology is headquartered
LocationHeadquarters
- HQ city
- San Francisco
- HQ country
- United States
- HQ region
- North America
Offices3 records
Markets served
Olema Oncology business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Marketing or Sales, Operations
Revenue model
- Product Revenue (Future): Pre-revenue clinical-stage biopharmaceutical company. Expected to generate product revenue from commercialization of palazestrant, anticipated to launch in 2027. No product revenue currently as all candidates are in clinical development.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels5 records
Olema Oncology product offering
Product offeringCore offering
Olema Oncology is a clinical-stage biopharmaceutical company developing novel targeted therapies for breast cancer. Its lead candidate, palazestrant (OP-1250), is an orally available complete estrogen receptor antagonist (CERAN) and selective estrogen receptor degrader (SERD) in pivotal Phase 3 trials for ER+/HER2- metastatic breast cancer. Its second candidate, OP-3136, is a selective KAT6 inhibitor in Phase 1 development for breast cancer and other solid tumors. Both are investigational small molecule therapeutics intended for regulatory approval and commercial sale upon completion of clinical development.
Product overview
Olema Oncology is a clinical-stage biopharmaceutical company developing targeted therapies for breast cancer. The company's product portfolio consists of two investigational drug candidates: palazestrant (OP-1250), the lead product, is a complete estrogen receptor antagonist (CERAN) and selective estrogen receptor degrader (SERD) in Phase 3 clinical trials for ER+/HER2- metastatic breast cancer; and OP-3136, an earlier-stage KAT6 inhibitor in Phase 1 development for breast cancer and other solid tumors. These two candidates represent the core offerings advancing through the company's clinical pipeline.
Differentiator
Problem solved
Functional benefit
Products and services
- Palazestrant (OP-1250) A novel, orally available complete estrogen receptor antagonist (CERAN) and selective estrogen receptor degrader (SERD) that blocks both transcriptional activation function domains AF1 and AF2 of the estrogen receptor, resulting in complete inhibition of ER-driven transcription regardless of ESR1 mutation status. Being evaluated as a single agent in the pivotal Phase 3 OPERA-01 trial and in combination with ribociclib in the pivotal Phase 3 OPERA-02 trial for ER+/HER2- metastatic breast cancer patients.
- OP-3136 A novel, orally available small molecule that potently and selectively inhibits lysine acetyltransferase 6 (KAT6), an epigenetic target dysregulated in breast and other cancers. Shows evidence of anti-tumor activity across multiple solid tumor types including ER+/HER2- advanced breast cancer, metastatic castration-resistant prostate cancer, and metastatic non-small cell lung cancer. Currently in Phase 1 clinical trial.
Quantifiable outcome
- Phase 3 OPERA-01 trial readout expected in fall 2026
- +3 more outcomes
Companies that use Olema Oncology
Customer profileSegments2 records
Ideal customer profiles2 records
Olema Oncology technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Olema Oncology partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered core.
- BayercoreClinical trial collaboration and supply agreement to evaluate OP-3136 in combination with NUBEQA (darolutamide) in prostate cancer and other solid tumors.
- NovartiscoreClinical trial collaboration and supply agreement where Novartis supplies ribociclib (Kisqali) for the Phase 3 OPERA-02 trial evaluating palazestrant in combination with ribociclib for first-line treatment of ER+, HER2- advanced breast cancer. Trial initiation expected mid-2025.
- PfizercoreClinical collaboration for palazestrant in combination with palbociclib (Ibrance) in Phase 1b/2 studies for ER+, HER2- breast cancer treatment.
Scale indicators10 records
Recent moves6 records
Expansion highlights5 records
Olema Oncology competitors and assessment
Company assessmentDirect peers
- Menarini Group: Italian pharma company that, with Radius Health, developed and commercializes elacestrant (Orserdu), the first FDA-approved oral SERD for ER+/HER2- metastatic breast cancer. Direct competitor in the same mechanism class and indication Olema is targeting with palazestrant.
- Roche: Swiss pharma giant developing giredestrant, an oral SERD in Phase 3 development (persevERA trial) for ER+/HER2- metastatic breast cancer. Direct competitor with overlapping mechanism of action; Roche's failed persevERA trial recently caused a 25.8% decline in Olema's stock price.
- AstraZeneca: Global pharma developing camizestrant, a next-generation oral SERD in late-stage SERENA trials for ER+/HER2- breast cancer. Direct competitor in the oral endocrine therapy space with deep oncology commercial infrastructure that could pressure palazestrant's market entry.
- Arvinas: Clinical-stage biotech developing vepdegestrant (ARV-471), a PROTAC estrogen receptor degrader in Phase 3 development for ER+/HER2- breast cancer, partnered with Pfizer. Directly comparable as a late-stage ER-targeting oral therapy in the same indication.
- Radius Health: Biotech that originally developed elacestrant (Orserdu) before licensing to Menarini. Direct peer in oral SERD development for ER+/HER2- breast cancer and a useful precedent for clinical-to-commercial transitions in this space.
Emerging players
- Zentalis Pharmaceuticals: Clinical-stage oncology company developing ZN-c5, an oral SERD for ER+/HER2- breast cancer. Smaller emerging competitor with a similar mechanism of action and indication focus, providing a useful benchmark for clinical-stage SERD valuations.
- Sermonix Pharmaceuticals: Private oncology company developing lasofoxifene, an oral selective estrogen receptor modulator for ESR1-mutated ER+ metastatic breast cancer. Comparable as a niche oral endocrine therapy targeting similar biomarker-defined patient populations as palazestrant.
- H3 Biomedicine / Eisai: Eisai subsidiary developing H3B-6545, an oral selective estrogen receptor covalent antagonist (SERCA) for ER+ breast cancer. Comparable as a niche oral endocrine therapy developer targeting the same patient population with a differentiated covalent-binding mechanism.
Broad incumbents
- Pfizer: Major pharma partner of Olema (supplying palbociclib for combination studies) and a competitor through its Arvinas partnership for vepdegestrant. Provides a useful comparison as a dominant oncology incumbent with endocrine therapy franchise (Ibrance) and competing ER-degrader development program.
- Novartis: Major pharma partner of Olema, supplying ribociclib (Kisqali) for the OPERA-02 combination Phase 3 trial and participating in the $250M private placement. Provides a relevant incumbent benchmark with established CDK4/6 franchise and global oncology commercial reach.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
Olema Oncology social profiles
Digital presenceOlema Oncology financial estimates
Financial estimateRevenue estimate
Valuation estimate
Olema Oncology leadership team
Management profileNumber of profiles
Profiles16 records
Olema Oncology funding detail
Funding detailFunding overview
Funding rounds7 records
Investors22 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Olema Oncology M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Olema Oncology
What does Olema Oncology do?
Olema Oncology is a clinical-stage biopharmaceutical company developing novel targeted therapies for breast cancer. Its lead candidate, palazestrant (OP-1250), is an orally available complete estrogen receptor antagonist (CERAN) and selective estrogen receptor degrader (SERD) in pivotal Phase 3 trials for ER+/HER2- metastatic breast cancer. Its second candidate, OP-3136, is a selective KAT6 inhibitor in Phase 1 development for breast cancer and other solid tumors. Both are investigational small molecule therapeutics intended for regulatory approval and commercial sale upon completion of clinical development.
Is Olema Oncology a public or private company?
Olema Oncology is a public company. It is classified as public and is currently operating.
When was Olema Oncology founded?
Olema Oncology was founded in 2006. It employs 101 to 250 people.
Where is Olema Oncology based?
Olema Oncology is headquartered in San Francisco, United States, in the North America region.
How does Olema Oncology make money?
One revenue line is on record: product Revenue (Future).
Who are Olema Oncology's main competitors?
Direct peers on record are Menarini Group, Roche, AstraZeneca, Arvinas and Radius Health. Emerging players are Zentalis Pharmaceuticals, Sermonix Pharmaceuticals and H3 Biomedicine / Eisai. Broad incumbents are Pfizer and Novartis.
Does Olema Oncology have an API?
No public API is recorded for Olema Oncology.
What industry is Olema Oncology in?
Olema Oncology's product category is Oncology Drug Development. Its primary akta.pro industry code is HLAKAFAJ, Breast Oncology, with a secondary code of HLAKAFAB, Medical Oncology. Its NAICS code is 541714 and its SIC code is 2834.